The U.S. Chamber of Commerce today urged foreign governments to improve their intellectual property (IP) enforcement efforts, following the Office of the U.S. Trade Representative’s (USTR) release of its annual Special 301 Report.
While India’s economic ascent has been nothing short of miraculous, it is imperative that India take into account the importance of ensuring adequate IP rights as they consider expanding their trade and investment relationships globally.
As we conduct our obligatory reflections today, it is clear that 2012 was a big year for intellectual property and the GIPC. From the release of our IP Creates Jobs state-IP jobs study to the launch of our wildly successful international multimedia platform IP Delivers, GIPC’s work as champions for innovators and creators in 2012 makes us very excited for what’s to come in 2013. And believe us, there’s plenty to come.
Is developing new drugs too difficult?
This is a question that we often get asked at NZBIO. Every new drug that enters clinical trials has about a 1-in-10 chance of success. The drugs that do make it all the way are typically in the research and development phase (R&D) for more than a decade at a cost of more than a billion dollars, which clearly requires international investment for drug candidates discovered in New Zealand. So much time, So much money, so many failures in R&D, so why do it?
